Coronavirus disease 2019

Last updated

Coronavirus disease 2019
(COVID-19)
Other names
  • The coronavirus
  • 2019-nCoV acute respiratory disease
  • Novel coronavirus pneumonia [1] [2]
  • Severe pneumonia with novel pathogens [3]
Novel Coronavirus SARS-CoV-2.jpg
Pronunciation
Specialty Infectious disease
SymptomsFever, cough, fatigue, shortness of breath, loss of taste or smell; sometimes no symptoms at all [5] [6]
Complications Pneumonia, viral sepsis, acute respiratory distress syndrome, kidney failure, cytokine release syndrome
Usual onset2–14 days (typically 5) from infection
Duration5 days to 6+ months known
Causes Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Diagnostic method rRT-PCR testing, CT scan
Prevention Hand washing, face coverings, quarantine, social distancing [7]
Treatment Symptomatic and supportive
Frequency62,616,821 [8] confirmed cases
Deaths1,457,859 [8]

Coronavirus disease 2019 (COVID-19) is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first case was identified in Wuhan, China in December 2019.

Contents

Common symptoms of COVID-19 include fever, cough, fatigue, breathing difficulties, and loss of smell and taste. Symptoms begin one to fourteen days after exposure to the virus. While most people have mild symptoms, some people develop acute respiratory distress syndrome (ARDS). ARDS can be precipitated by cytokine storms, [9] multi-organ failure, septic shock, and blood clots. Longer-term damage to organs (in particular, the lungs and heart) has been observed. There is concern about a significant number of patients who have recovered from the acute phase of the disease but continue to experience a range of effects—known as long COVID—for months afterwards. These effects include severe fatigue, memory loss and other cognitive issues, low-grade fever, muscle weakness, and breathlessness. [10] [11] [12] [13]

COVID-19 spreads via a number of means, primarily involving saliva and other bodily fluids and excretions. These fluids can form small droplets and aerosols, which can spread as an infected person breathes, coughs, sneezes, sings, or speaks. The virus may also spread by direct contact and it is unknown how often it spreads via fomites (contaminated surfaces). [14] [15] The exact route of transmission is rarely proven conclusively, [16] but infection mainly happens when people are near each other for long enough, which is known as "close contact". [lower-alpha 1] It can spread as early as two days before infected persons show symptoms (presymptomatic), and from asymptomatic individuals. People remain infectious for up to ten days in moderate cases, and two weeks in severe cases. The standard diagnosis method is by real-time reverse transcription polymerase chain reaction (rRT-PCR) from a nasopharyngeal swab.

Preventive measures include social distancing, quarantining, ventilation of indoor spaces, covering coughs and sneezes, hand washing, and keeping unwashed hands away from the face. The use of face masks or coverings has been recommended in public settings to minimise the risk of transmissions.

There are currently no proven vaccines or specific treatments for COVID-19, though several are in development. Management involves the treatment of symptoms, supportive care, isolation, and experimental measures.

Signs and symptoms

Symptoms of COVID-19 Symptoms of coronavirus disease 2019 4.0.svg
Symptoms of COVID-19

Symptoms of COVID-19 are variable, but usually include fever and a cough. [21] [22] People with the same infection may have different symptoms, and their symptoms may change over time. For example, one person may have a high fever, a cough, and fatigue, and another person may have a low fever at the start of the disease and develop difficulty breathing a week later. However, in people without prior ears, nose, and throat (ENT) disorders, loss of taste combined with loss of smell is associated with COVID-19 with a specificity of 95%. [23]

As is common with infections, there is a delay, known as the incubation period, between the moment a person first becomes infected and the appearance of the first symptoms. The median incubation period for COVID-19 is four to five days. [24] Most symptomatic people experience symptoms within two to seven days after exposure, and almost all symptomatic people will experience one or more symptoms before day twelve. [24] [25]

Around one in five people are infected with the virus but do not develop noticeable symptoms at any point in time. [26] [27] These asymptomatic carriers tend not to get tested, and they can spread the disease. [28] [29] [27] Other infected people will develop symptoms later (called pre-symptomatic) or have very mild symptoms, and can also spread the virus. [30]

Cause

COVID-19 is caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus strain.

Transmission

COVID-19 spreads from person to person mainly through the respiratory route after an infected person coughs, sneezes, sings, talks or breathes. A new infection occurs when virus-containing particles exhaled by an infected person, either respiratory droplets or aerosols, get into the mouth, nose, or eyes of other people who are in close contact with the infected person. [31] [32]

The closer people interact, and the longer they interact, the more likely they are to transmit COVID-19. Closer distances can involve larger droplets (which fall to the ground) and aerosols, whereas longer distances only involve aerosols. The larger droplets may also evaporate into the aerosols (known as droplet nuclei). The relative importance of the larger droplets and the aerosols is not clear as of November 2020, however the virus is not known to transmit between rooms over long distances such as through air ducts. Airborne transmission is able to particularly occur indoors, in high risk locations, such as in restaurants, choirs, gyms, nightclubs, offices, and religious venues, often when they are crowded or less ventilated. It also occurs in healthcare settings, often when aerosol-generating medical procedures are performed on COVID-19 patients.

Social distancing and the wearing of cloth face masks, surgical masks, respirators, or other face coverings are controls for droplet transmission. Transmission may be decreased indoors with well maintained heating and ventilation systems to maintain good air circulation and increase the use of outdoor air. [32]

The number of people generally infected by one infected person varies; as of September 2020 it was estimated that one infected person will, on average, infect between two and three other people. [33] This is more infectious than influenza, but less so than measles. [34] It often spreads in clusters, where infections can be traced back to an index case or geographical location. There is a major role of "super-spreading events", where many people are infected by one person.

Virology

Illustration of SARSr-CoV virion Coronavirus virion structure.svg
Illustration of SARSr-CoV virion

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel severe acute respiratory syndrome coronavirus. It was first isolated from three people with pneumonia connected to the cluster of acute respiratory illness cases in Wuhan. [35] All features of the novel SARS-CoV-2 virus occur in related coronaviruses in nature. [36]

Outside the human body, the virus is destroyed by household soap, which bursts its protective bubble. [37]

SARS-CoV-2 is closely related to the original SARS-CoV. [38] It is thought to have an animal (zoonotic) origin. Genetic analysis has revealed that the coronavirus genetically clusters with the genus Betacoronavirus , in subgenus Sarbecovirus (lineage B) together with two bat-derived strains. It is 96% identical at the whole genome level to other bat coronavirus samples (BatCov RaTG13). [39] [40] The structural proteins of SARS-CoV-2 include membrane glycoprotein (M), envelope protein (E), nucleocapsid protein (N), and the spike protein (S). The M protein of SARS-CoV-2 is 98.6% similar to the M protein of bat SARS-CoV, maintains 98.2% homology with pangolin SARS-CoV, and has 90% homology with the M protein of SARS-CoV; whereas, the similarity is only 38% with the M protein of MERS-CoV. In silico analyses showed that the M protein of SARS-CoV-2 has a triple helix bundle, forms a single 3-transmembrane domain, and is homologous to the prokaryotic sugar transport protein SemiSWEET. [41]

Pathophysiology

COVID-19 can affect the upper respiratory tract (sinuses, nose, and throat) and the lower respiratory tract (windpipe and lungs). [42] The lungs are the organs most affected by COVID-19 because the virus accesses host cells via the enzyme angiotensin-converting enzyme 2 (ACE2), which is most abundant in type II alveolar cells of the lungs. [43] The virus uses a special surface glycoprotein called a "spike" (peplomer) to connect to ACE2 and enter the host cell. [44] The density of ACE2 in each tissue correlates with the severity of the disease in that tissue and some have suggested decreasing ACE2 activity might be protective, [45] though another view is that increasing ACE2 using angiotensin II receptor blocker medications could be protective. [46] As the alveolar disease progresses, respiratory failure might develop and death may follow. [47]

Whether SARS-CoV-2 is able to invade the nervous system remains unknown. The virus is not detected in the CNS of the majority of COVID-19 patients with neurological issues. However, SARS-CoV-2 has been detected at low levels in the brains of patients who died from COVID-19, but these results need to be confirmed. [48] SARS-CoV-2 may cause respiratory failure through affecting the brain stem as other coronaviruses have been found to invade the CNS. While virus has been detected in cerebrospinal fluid of autopsies, the exact mechanism by which it invades the CNS remains unclear and may first involve invasion of peripheral nerves given the low levels of ACE2 in the brain. [49] [50] [51] The virus may also enter the bloodstream from the lungs and cross the blood-brain barrier to gain access to the CNS, possibly within an infected white blood cell by a "Trojan horse" mechanism. [48]

The virus also affects gastrointestinal organs as ACE2 is abundantly expressed in the glandular cells of gastric, duodenal and rectal epithelium [52] as well as endothelial cells and enterocytes of the small intestine. [53]

The virus can cause acute myocardial injury and chronic damage to the cardiovascular system. [54] An acute cardiac injury was found in 12% of infected people admitted to the hospital in Wuhan, China, [55] and is more frequent in severe disease. [56] Rates of cardiovascular symptoms are high, owing to the systemic inflammatory response and immune system disorders during disease progression, but acute myocardial injuries may also be related to ACE2 receptors in the heart. [54] ACE2 receptors are highly expressed in the heart and are involved in heart function. [54] [57] A high incidence of thrombosis and venous thromboembolism have been found in intensive care unit (ICU)-transferred patients with COVID-19 infections, and may be related to poor prognosis. [58] Blood vessel dysfunction and clot formation (as suggested by high D-dimer levels) are thought to play a significant role in mortality, incidences of clots leading to pulmonary embolisms, and ischaemic events within the brain have been noted as complications leading to death in patients infected with SARS-CoV-2. Infection appears to set off a chain of vasoconstrictive responses within the body, constriction of blood vessels within the pulmonary circulation has also been posited as a mechanism in which oxygenation decreases alongside the presentation of viral pneumonia. [59]

Another common cause of death is complications related to the kidneys. [59] Early reports show that up to 30% of hospitalized patients both in China and in New York have experienced some injury to their kidneys, including some persons with no previous kidney problems. [60]

Autopsies of people who died of COVID-19 have found diffuse alveolar damage (DAD), and lymphocyte-containing inflammatory infiltrates within the lung. [61]

Immunopathology

Although SARS-CoV-2 has a tropism for ACE2-expressing epithelial cells of the respiratory tract, patients with severe COVID-19 have symptoms of systemic hyperinflammation. Clinical laboratory findings of elevated IL-2, IL-7, IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-γ inducible protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), Macrophage inflammatory protein 1-α (MIP-1α), and tumour necrosis factor-α (TNF-α) indicative of cytokine release syndrome (CRS) suggest an underlying immunopathology. [55]

Additionally, people with COVID-19 and acute respiratory distress syndrome (ARDS) have classical serum biomarkers of CRS, including elevated C-reactive protein (CRP), lactate dehydrogenase (LDH), D-dimer, and ferritin. [62]

Systemic inflammation results in vasodilation, allowing inflammatory lymphocytic and monocytic infiltration of the lung and the heart. In particular, pathogenic GM-CSF-secreting T-cells were shown to correlate with the recruitment of inflammatory IL-6-secreting monocytes and severe lung pathology in COVID-19 patients. [63] Lymphocytic infiltrates have also been reported at autopsy. [61]

Diagnosis

Demonstration of a nasopharyngeal swab for COVID-19 testing Infektionsschutzzentrum im Rautenstrauch-Joest-Museum, Koln-6313 (cropped).jpg
Demonstration of a nasopharyngeal swab for COVID-19 testing
US CDC rRT-PCR test kit for COVID-19 CDC 2019-nCoV Laboratory Test Kit.jpg
US CDC rRT-PCR test kit for COVID-19

The WHO has published several testing protocols for the disease. [65] The standard method of testing is real-time reverse transcription polymerase chain reaction (rRT-PCR). [66] The test is typically done on respiratory samples obtained by a nasopharyngeal swab; however, a nasal swab or sputum sample may also be used. [67] [68] Results are generally available within a few hours to two days. [69] [70] Blood tests can be used, but these require two blood samples taken two weeks apart, and the results have little immediate value. [71] Chinese scientists were able to isolate a strain of the coronavirus and publish the genetic sequence so laboratories across the world could independently develop polymerase chain reaction (PCR) tests to detect infection by the virus. [72] [73] [74] As of 4 April 2020, antibody tests (which may detect active infections and whether a person had been infected in the past) were in development, but not yet widely used. [75] [76] [77] Antibody tests may be most accurate 2–3 weeks after a person's symptoms start. [78] The Chinese experience with testing has shown the accuracy is only 60 to 70%. [79] The US Food and Drug Administration (FDA) approved the first point-of-care test on 21 March 2020 for use at the end of that month. [80] The absence or presence of COVID-19 signs and symptoms alone is not reliable enough for an accurate diagnosis. [81] Different clinical scores were created based on symptoms, laboratory parameters and imaging to determine patients with probable SARS-CoV-2 infection or more severe stages of COVID-19. [82] [83]

Diagnostic guidelines released by Zhongnan Hospital of Wuhan University suggested methods for detecting infections based upon clinical features and epidemiological risk. These involved identifying people who had at least two of the following symptoms in addition to a history of travel to Wuhan or contact with other infected people: fever, imaging features of pneumonia, normal or reduced white blood cell count, or reduced lymphocyte count. [84]

A study asked hospitalised COVID-19 patients to cough into a sterile container, thus producing a saliva sample, and detected the virus in eleven of twelve patients using RT-PCR. This technique has the potential of being quicker than a swab and involving less risk to health care workers (collection at home or in the car). [85]

Along with laboratory testing, chest CT scans may be helpful to diagnose COVID-19 in individuals with a high clinical suspicion of infection but are not recommended for routine screening. [86] [87] Bilateral multilobar ground-glass opacities with a peripheral, asymmetric, and posterior distribution are common in early infection. [86] [88] Subpleural dominance, crazy paving (lobular septal thickening with variable alveolar filling), and consolidation may appear as the disease progresses. [86] [89]

In late 2019, the WHO assigned emergency ICD-10 disease codes U07.1 for deaths from lab-confirmed SARS-CoV-2 infection and U07.2 for deaths from clinically or epidemiologically diagnosed COVID-19 without lab-confirmed SARS-CoV-2 infection. [90]

Pathology

The main pathological findings at autopsy are: [61]

Prevention

Without pandemic containment measures--such as social distancing, vaccination, and use of face masks--pathogens can spread exponentially. This graphic shows how early adoption of containment measures tends to protect wider swaths of the population. 20200609 Effect of pandemic containment measures.gif
Without pandemic containment measures—such as social distancing, vaccination, and use of face masks—pathogens can spread exponentially. This graphic shows how early adoption of containment measures tends to protect wider swaths of the population.
Progressively stronger mitigation efforts to reduce the number of active cases at any given time--"flattening the curve"--allows healthcare services to better manage the same volume of patients. Likewise, progressively greater increases in healthcare capacity--called raising the line--such as by increasing bed count, personnel, and equipment, helps to meet increased demand. 20200410 Flatten the curve, raise the line - pandemic (English).gif
Progressively stronger mitigation efforts to reduce the number of active cases at any given time—"flattening the curve"—allows healthcare services to better manage the same volume of patients. Likewise, progressively greater increases in healthcare capacity—called raising the line—such as by increasing bed count, personnel, and equipment, helps to meet increased demand.
Mitigation attempts that are inadequate in strictness or duration--such as premature relaxation of distancing rules or stay-at-home orders--can allow a resurgence after the initial surge and mitigation. 20200409 Pandemic resurgence - effect of inadequate mitigation.gif
Mitigation attempts that are inadequate in strictness or duration—such as premature relaxation of distancing rules or stay-at-home orders—can allow a resurgence after the initial surge and mitigation.

A COVID-19 vaccine is not expected until 2021 at the earliest. [100] The US National Institutes of Health guidelines do not recommend any medication for prevention of COVID-19, before or after exposure to the SARS-CoV-2 virus, outside the setting of a clinical trial. [101] [102] Without a vaccine, other prophylactic measures, or effective treatments, a key part of managing COVID-19 is trying to decrease and delay the epidemic peak, known as "flattening the curve". [96] This is done by slowing the infection rate to decrease the risk of health services being overwhelmed, allowing for better treatment of current cases, and delaying additional cases until effective treatments or a vaccine become available. [96] [99]

Preventive measures to reduce the chances of infection include staying at home, wearing a mask in public, avoiding crowded places, keeping distance from others, ventilating indoor spaces, washing hands with soap and water often and for at least 20 seconds, practising good respiratory hygiene, and avoiding touching the eyes, nose, or mouth with unwashed hands. [103] [104] [105] [106] [107] Those diagnosed with COVID-19 or who believe they may be infected are advised by the CDC to stay home except to get medical care, call ahead before visiting a healthcare provider, wear a face mask before entering the healthcare provider's office and when in any room or vehicle with another person, cover coughs and sneezes with a tissue, regularly wash hands with soap and water and avoid sharing personal household items. [108] [109]

Personal protective equipment

For health care professionals who may come into contact with COVID-19 positive bodily fluids, using personal protective coverings on exposed body parts improves protection from the virus. [110] Breathable personal protective equipment[ clarification needed ] improves user-satisfaction and may offer a similar level of protection from the virus. [110] In addition, adding tabs and other modifications to the protective equipment may reduce the risk of contamination during donning and doffing (putting on and taking off the equipment). [110] Implementing an evidence-based donning and doffing protocol such as a one-step glove and gown removal technique, giving oral instructions while donning and doffing, double gloving, and the use of glove disinfection may also improve protection for health care professionals. [110]

Face masks

The World Health Organization (WHO) and most government health agencies (such as the US Centers for Disease Control and Prevention (CDC), the UK National Health Service (NHS), or the New Zealand Ministry of Health) recommend individuals wear non-medical face coverings in public settings where there is an increased risk of transmission and where social distancing measures are difficult to maintain. [111] [112] [113] [114] [115] This recommendation is meant to reduce the spread of the disease by asymptomatic and pre-symptomatic individuals and is complementary to established preventive measures such as social distancing. [112] [116] Face coverings limit the volume and travel distance of expiratory droplets dispersed when talking, breathing, and coughing. [112] [116] Many countries and local jurisdictions encourage or mandate the use of face masks or cloth face coverings by members of the public to limit the spread of the virus. [117] [118] [119] [120]

Masks are also strongly recommended for those who may have been infected and those taking care of someone who may have the disease. [121]

Social distancing

Social distancing measures on the castle of Kavala, Greece Kastro, Kavala.jpg
Social distancing measures on the castle of Kavala, Greece

Social distancing strategies aim to reduce contact of infected persons within large groups by closing schools and workplaces, restricting travel, and cancelling large public gatherings. [122] Distancing guidelines also include that people stay at least 2 metres (6.6 ft) apart. [123] After the implementation of social distancing and stay-at-home orders, many regions have been able to sustain an effective transmission rate ("Rt") of less than one, meaning the disease is in remission in those areas. [124]

Hand-washing and hygiene

When not wearing a mask, the CDC, WHO, and NHS recommends covering the mouth and nose with a tissue when coughing or sneezing and recommends using the inside of the elbow if no tissue is available. [104] [114] [125] Proper hand hygiene after any cough or sneeze is encouraged. [104] [114] The WHO also recommends that individuals wash hands often with soap and water for at least 20 seconds, especially after going to the toilet or when hands are visibly dirty, before eating and after blowing one's nose. [125] The CDC recommends using an alcohol-based hand sanitiser with at least 60% alcohol, but only when soap and water are not readily available. [114] For areas where commercial hand sanitisers are not readily available, the WHO provides two formulations for local production. In these formulations, the antimicrobial activity arises from ethanol or isopropanol. Hydrogen peroxide is used to help eliminate bacterial spores in the alcohol; it is "not an active substance for hand antisepsis". Glycerol is added as a humectant. [126]

Sanitizing of frequently touched surfaces is also recommended or required by regulation for businesses and public facilities; the United States Environmental Protection Agency maintains a list of products expected to be effective. [127]

Management

The management of COVID-19 includes supportive care, which may include fluid therapy, oxygen support, and supporting other affected vital organs. [128] [129] [130] The WHO is in the process of including dexamethasone in guidelines for treatment for hospitalized patients, and it is recommended for consideration in Australian guidelines for patients requiring oxygen. [131] [132] CDC recommends those who suspect they carry the virus wear a simple face mask. [133] Extracorporeal membrane oxygenation (ECMO) has been used to address the issue of respiratory failure, but its benefits are still under consideration. [134] [135] Personal hygiene and a healthy lifestyle and diet have been recommended to improve immunity. [136] Supportive treatments may be useful in those with mild symptoms at the early stage of infection. [137] Nasal breathing is suggested as such a procedure based on several peer reviewed studies. [138] [139]

The WHO, the Chinese National Health Commission, and the United States' National Institutes of Health have published recommendations for taking care of people who are hospitalised with COVID‑19. [140] [141] [142] Intensivists and pulmonologists in the U.S. have compiled treatment recommendations from various agencies into a free resource, the IBCC. [143] [144]

Prognosis

Severity-of-coronavirus-cases-in-China-1.svg
The severity of diagnosed COVID-19 cases in China [145]
COVID-CFR-by-age-CN-KR-ES-IT-latest-nolegend.svg
Case fatality rates by age group:
  China, as of 11 February 2020 [146]
  South Korea, as of 17 July 2020 [147]
  Spain, as of 18 May 2020 [148]
  Italy, as of 3 June 2020 [149]
Covid-19-total-confirmed-cases-vs-total-confirmed-deaths.svg
The number of deaths vs total cases by country and approximate case fatality rate [150]

The severity of COVID-19 varies. The disease may take a mild course with few or no symptoms, resembling other common upper respiratory diseases such as the common cold. Mild cases typically recover within two weeks, while those with severe or critical diseases may take three to six weeks to recover. Among those who have died, the time from symptom onset to death has ranged from two to eight weeks. [39] The Italian Istituto Superiore di Sanità reported that the median time between the onset of symptoms and death was twelve days, with seven being spent hospitalised. However, people transferred to an ICU had a median time of ten days between hospitalisation and death. [151] Prolonged prothrombin time and elevated C-reactive protein levels on admission to the hospital are associated with severe course of COVID-19 and with a transfer to ICU. [152] [153]

Some early studies suggest 10% to 20% of people with COVID-19 will experience symptoms lasting longer than a month. [154] [155] A majority of those who were admitted to hospital with severe disease report long-term problems including fatigue and shortness of breath. [156] On 30 October 2020 WHO chief Tedros has warned that "to a significant number of people, the COVID virus poses a range of serious long-term effects". He has described the vast spectrum of COVID-19 symptoms that fluctuate over time as "really concerning." They range from fatigue, a cough and shortness of breath, to inflammation and injury of major organs – including the lungs and heart, and also neurological and psychologic effects. Symptoms often overlap and can affect any system in the body. Infected people have reported cyclical bouts of fatigue, headaches, months of complete exhaustion, mood swings and other symptoms. Tedros has underlined that therefore herd immunity is "morally unconscionable and unfeasible". [157]

In terms of hospital readmissions about 9% of 106,000 individuals had to return for hospital treatment within 2 months of discharge. The average to readmit was 8 days since first hospital visit.There are several risk factors that have been identified as being a cause of multiple admissions to a hospital facility. Among these are advanced age (above 65 years of age) and presence of a chronic condition such as diabetes, COPD, heart failure or chronic kidney disease. [158] [159]

According to scientific reviews smokers are more likely to require intensive care or die compared to non-smokers, [160] [161] air pollution is similarly associated with risk factors, [161] and pre-existing heart and lung diseases [162] and also obesity contributes to an increased health risk of COVID-19. [161] [163] [164]

It is also assumed that those that are immunocompromised are at higher risk of getting severely sick from SARS-CoV-2. [165] One research that looked into the COVID-19 infections in hospitalized kidney transplant recipients found a mortality rate of 11%. [166]

Children make up a small proportion of reported cases, with about 1% of cases being under 10 years and 4% aged 10–19 years. [167] They are likely to have milder symptoms and a lower chance of severe disease than adults.

A European multinational study of hospitalized children published in The Lancet on 25 June 2020 found that about 8% of children admitted to a hospital needed intensive care. Four of those 582 children (0.7%) died, but the actual mortality rate could be "substantially lower" since milder cases that did not seek medical help were not included in the study. [168]

Mortality rates are highly correlated to age. In those younger than 50 years the risk of death is less than 0.5%, while in those older than 70 it is more than 8%. [169] [170] [171] According to a CDC analysis, the risk of death by age groups in the United States is 0.003%, 0.02%; 0.5% and 5.4% for the age groups 0–19, 20–49, 50–69, and 70 or over, respectively. [172] [173]

Genetics also plays an important role in the ability to fight off the disease. For instance, those that do not produce detectable type I interferons or produce auto-antibodies against these may get much sicker from COVID-19. [174] [175] Genetic screening is able to detect interferon effector genes. [176]

Pregnant women may be at higher risk of severe COVID-19 infection based on data from other similar viruses, like severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), but data for COVID-19 is lacking. [177] [178]

Historical COVID-19 CFR (%) by age and region
Age
Country0–910–1920–2930–3940–4950–5960–6970–7980–8990+
Argentina as of 7 May [179] 0.00.00.10.41.33.612.918.828.4
Australia as of 4 June [180] 0.00.00.00.00.10.21.14.118.140.8
Canada as of 3 June [181] 0.00.10.711.230.7
    Alberta as of 3 June [182] 0.00.00.10.10.10.21.911.930.8
    Br. Columbia as of 2 June [183] 0.00.00.00.00.50.84.612.333.833.6
    Ontario as of 3 June [184] 0.00.00.10.20.51.55.617.726.033.3
    Quebec as of 2 June [185] 0.00.10.10.21.16.121.430.436.1
Chile as of 31 May [186] [187] 0.10.30.72.37.715.6
China as of 11 February [188] 0.00.20.20.20.41.33.68.014.8
Colombia as of 3 June [189] 0.30.00.20.51.63.49.418.125.635.1
Denmark as of 4 June [190] 0.24.116.528.148.2
Finland as of 4 June [191] 0.00.0<0.4<0.4<0.50.83.818.142.3
Germany as of 5 June [192] 0.00.00.11.919.731.0
   Bavaria as of 5 June [193] 0.00.00.10.10.20.95.415.828.035.8
Israel as of 3 May [194] 0.00.00.00.90.93.19.722.930.831.3
Italy as of 3 June [195] 0.30.00.10.30.92.710.625.932.429.9
Japan as of 7 May [196] 0.00.00.00.10.30.62.56.814.8
Mexico as of 3 June [197] 3.30.61.22.97.515.025.333.740.340.6
Netherlands as of 3 June [198] 0.00.20.10.30.51.78.125.633.334.5
Norway as of 4 June [199] 0.00.00.00.00.30.42.29.022.757.0
Philippines as of 4 June [200] 1.60.90.50.82.45.513.220.931.5
Portugal as of 3 June [201] 0.00.00.00.00.31.33.610.521.2
South Africa as of 28 May [202] 0.30.10.10.41.13.89.215.012.3
South Korea as of 17 July [203] 0.00.00.00.10.20.62.39.525.2
Spain as of 29 May [204] 0.30.20.20.30.61.45.014.320.821.7
Sweden as of 5 June [205] 0.50.00.20.20.61.76.623.435.640.3
Switzerland as of 4 June [206] 0.60.00.00.10.10.63.411.628.2
United States
    Colorado as of 3 June [207] 0.20.20.20.20.81.96.218.539.0
    Connecticut as of 3 June [208] 0.20.10.10.30.71.87.018.031.2
    Georgia as of 3 June [209] 0.00.10.50.92.06.113.222.0
    Idaho as of 3 June [210] 0.00.00.00.00.00.43.18.931.4
    Indiana as of 3 June [211] 0.10.10.20.61.87.317.130.2
    Kentucky as of 20 May [212] 0.00.00.00.20.51.95.914.229.1
    Maryland as of 20 May [213] 0.00.10.20.30.71.96.114.628.8
    Massachusetts as of 20 May [214] 0.00.00.10.10.41.55.216.828.9
    Minnesota as of 13 May [215] 0.00.00.00.10.31.65.426.9
    Mississippi as of 19 May [216] 0.00.10.50.92.18.116.119.427.2
    Missouri as of 19 May [217] 0.00.00.10.20.82.26.314.322.5
    Nevada as of 20 May [218] 0.00.30.30.41.72.67.722.3
    N. Hampshire as of 12 May [219] 0.00.00.40.01.20.02.212.021.2
    Oregon as of 12 May [220] 0.00.00.00.00.50.85.612.128.9
    Texas as of 20 May [221] 0.00.50.40.30.82.15.510.130.6
    Virginia as of 19 May [222] 0.00.00.00.10.41.04.412.924.9
    Washington as of 10 May [223] 0.00.21.39.831.2
    Wisconsin as of 20 May [224] 0.00.00.20.20.62.05.014.719.930.4

Comorbidities

Most of those who die of COVID-19 have pre-existing (underlying) conditions, including hypertension, diabetes mellitus, and cardiovascular disease. [225] According to March data from the United States, 89% of those hospitalised had preexisting conditions. [226] The Italian Istituto Superiore di Sanità reported that out of 8.8% of deaths where medical charts were available, 96.1% of people had at least one comorbidity with the average person having 3.4 diseases. [151] According to this report the most common comorbidities are hypertension (66% of deaths), type 2 diabetes (29.8% of deaths), ischemic heart disease (27.6% of deaths), atrial fibrillation (23.1% of deaths) and chronic renal failure (20.2% of deaths).

Most critical respiratory comorbidities according to the CDC, are: moderate or severe asthma, pre-existing COPD, pulmonary fibrosis, cystic fibrosis. [227] Evidence stemming from meta-analysis of several smaller research papers also suggests that smoking can be associated with worse patient outcomes. [228] [229] When someone with existing respiratory problems is infected with COVID-19, they might be at greater risk for severe symptoms. [230] COVID-19 also poses a greater risk to people who misuse opioids and methamphetamines, insofar as their drug use may have caused lung damage. [231]

In August 2020 the CDC issued caution that tuberculosis infections could increase the risk of severe illness or death. The WHO recommended that patients with respiratory symptoms be screened for both diseases, as testing positive for COVID-19 couldn't rule out co-infections. Some projections have estimated that reduced TB detection due to the pandemic could result in 6.3 million additional TB cases and 1.4 million TB related deaths by 2025. [232]

Complications

Complications may include pneumonia, acute respiratory distress syndrome (ARDS), multi-organ failure, septic shock, and death. [72] [233] [234] [235] [236]

Cardiovascular complications may include heart failure, arrhythmias, heart inflammation, and blood clots. [237]

Approximately 20–30% of people who present with COVID-19 have elevated liver enzymes reflecting liver injury. [102] [238]

Neurologic manifestations include seizure, stroke, encephalitis, and Guillain–Barré syndrome (which includes loss of motor functions). [239] [240] Following the infection, children may develop paediatric multisystem inflammatory syndrome, which has symptoms similar to Kawasaki disease, which can be fatal. [241] [242] In very rare cases, acute encephalopathy can occur, and it can be considered in those who have been diagnosed with COVID-19 and have an altered mental status. [243]

Longer-term effects

Some early studies [154] [244] suggest between 1 in 5 and 1 in 10 people with COVID-19 will experience symptoms lasting longer than a month. A majority of those who were admitted to hospital with severe disease report long-term problems including fatigue and shortness of breath. [156]

On 30 October 2020 WHO chief Tedros has warned that "to a significant number of people, the COVID virus poses a range of serious long-term effects". He has described the vast spectrum of COVID-19 symptoms that fluctuate over time as "really concerning." They range from fatigue, a cough and shortness of breath, to inflammation and injury of major organs – including the lungs and heart, and also neurological and psychologic effects. Symptoms often overlap and can affect any system in the body. Infected people have reported cyclical bouts of fatigue, headaches, months of complete exhaustion, mood swings and other symptoms. Tedros has underlined that therefore herd immunity is “morally unconscionable and unfeasible”. [245]

Immunity

The immune response by humans to CoV-2 virus occurs as a combination of the cell-mediated immunity and antibody production, [246] just as with most other infections. [247] However, it remains unknown if the immunity is long-lasting in people who recover from the disease.[ needs update ] [248] Cases in which recovery from COVID-19 was followed by positive tests for coronavirus at a later date have been reported. In some of these cases, the RNA from the first and second infections indicates a different strain of the virus. [249] [250] [251] [252] Some reinfection cases are believed to be lingering infection rather than reinfection, [252] or false positives due to remaining, non-infectious RNA fragments. [253] Some other coronaviruses circulating in people are capable of reinfection after roughly a year. [254]

History

The virus is thought to be natural and has an animal origin, [36] through spillover infection. [255] The first known human infections were in Wuhan, Hubei, China. A study of the first 41 cases of confirmed COVID-19, published in January 2020 in The Lancet , reported the earliest date of onset of symptoms as 1 December 2019. [256] [257] [258] Official publications from the WHO reported the earliest onset of symptoms as 8 December 2019. [259] Human-to-human transmission was confirmed by the WHO and Chinese authorities by 20 January 2020. [260] [261] According to official Chinese sources, these were mostly linked to the Huanan Seafood Wholesale Market, which also sold live animals. [262] In May 2020, George Gao, the director of the Chinese Center for Disease Control and Prevention, said animal samples collected from the seafood market had tested negative for the virus, indicating that the market was the site of an early superspreading event, but it was not the site of the initial outbreak. [263] Traces of the virus have been found in wastewater that was collected from Milan and Turin, Italy, on 18 December 2019. [264]

There are several theories about where the first case (the so-called patient zero) originated. [265] According to an unpublicised report from the Chinese government, the first case can be traced back to 17 November 2019; the person was a 55-year-old citizen in the Hubei province.[ citation needed ] There were four men and five women reported to be infected in November, but none of them were "patient zero".[ citation needed ] By December 2019, the spread of infection was almost entirely driven by human-to-human transmission. [146] [266] The number of coronavirus cases in Hubei gradually increased, reaching 60 by 20 December [267] and at least 266 by 31 December. [268] On 24 December, Wuhan Central Hospital sent a bronchoalveolar lavage fluid (BAL) sample from an unresolved clinical case to sequencing company Vision Medicals. On 27 and 28 December, Vision Medicals informed the Wuhan Central Hospital and the Chinese CDC of the results of the test, showing a new coronavirus. [269] A pneumonia cluster of unknown cause was observed on 26 December and treated by the doctor Zhang Jixian in Hubei Provincial Hospital, who informed the Wuhan Jianghan CDC on 27 December. [270] On 30 December, a test report addressed to Wuhan Central Hospital, from company CapitalBio Medlab, stated an erroneous positive result for SARS, causing a group of doctors at Wuhan Central Hospital to alert their colleagues and relevant hospital authorities of the result. That evening, the Wuhan Municipal Health Commission issued a notice to various medical institutions on "the treatment of pneumonia of unknown cause". [271] Eight of these doctors, including Li Wenliang (punished on 3 January), [272] were later admonished by the police for spreading false rumours, and another, Ai Fen, was reprimanded by her superiors for raising the alarm. [273]

The Wuhan Municipal Health Commission made the first public announcement of a pneumonia outbreak of unknown cause on 31 December, confirming 27 cases [274] [275] [276] —enough to trigger an investigation. [277]

During the early stages of the outbreak, the number of cases doubled approximately every seven and a half days. [278] In early and mid-January 2020, the virus spread to other Chinese provinces, helped by the Chinese New Year migration and Wuhan being a transport hub and major rail interchange. [39] On 20 January, China reported nearly 140 new cases in one day, including two people in Beijing and one in Shenzhen. [279] Later official data shows 6,174 people had already developed symptoms by then, [280] and more may have been infected. [281] A report in The Lancet on 24 January indicated human transmission, strongly recommended personal protective equipment for health workers, and said testing for the virus was essential due to its "pandemic potential". [55] [282] On 30 January, the WHO declared the coronavirus a Public Health Emergency of International Concern. [281] By this time, the outbreak spread by a factor of 100 to 200 times. [283]

On 31 January 2020, Italy had its first confirmed cases, two tourists from China. [284] As of 13 March 2020, the World Health Organization (WHO) considered Europe the active centre of the pandemic. [285] On 19 March 2020, Italy overtook China as the country with the most deaths. [286] By 26 March, the United States had overtaken China and Italy with the highest number of confirmed cases in the world. [287] Research on coronavirus genomes indicates the majority of COVID-19 cases in New York came from European travellers, rather than directly from China or any other Asian country. [288] Retesting of prior samples found a person in France who had the virus on 27 December 2019 [289] [290] and a person in the United States who died from the disease on 6 February 2020. [291]

On 11 June 2020, after 55 days without a locally transmitted case, [292] Beijing reported the first COVID-19 case, followed by two more cases on 12 June. [293] By 15 June 79 cases were officially confirmed. [294] Most of these patients went to Xinfadi Wholesale Market. [292] [295]

Possible earlier cases

Research in Italy on samples from 959 volunteers in an experimental lung cancer treatment undertaken from September 2019 have shown COVID-19 anti-bodies in 14% of the samples. National Cancer Institute in Milan director Giovanni Apolone suggests that the major outbreak in Italy could have been caused because COVID-19 was wide spread in Italy from Summer 2019. [296]

Epidemiology

Several measures are commonly used to quantify mortality. [297] These numbers vary by region and over time and are influenced by the volume of testing, healthcare system quality, treatment options, time since the initial outbreak, and population characteristics such as age, sex, and overall health. [298]

The death-to-case ratio reflects the number of deaths divided by the number of diagnosed cases within a given time interval. Based on Johns Hopkins University statistics, the global death-to-case ratio is

Other measures include the case fatality rate (CFR), which reflects the percentage of diagnosed individuals who die from a disease, and the infection fatality rate (IFR), which reflects the percentage of infected individuals (diagnosed and undiagnosed) who die from a disease. These statistics are not time-bound and follow a specific population from infection through case resolution. Many academics have attempted to calculate these numbers for specific populations. [300]

Outbreaks have occurred in prisons due to crowding and an inability to enforce adequate social distancing. [301] [302] In the United States, the prisoner population is aging and many of them are at high risk for poor outcomes from COVID-19 due to high rates of coexisting heart and lung disease, and poor access to high-quality healthcare. [301]

Total-cases-covid-19-who.png
Total confirmed cases over time
Total-deaths-covid-19-who (1).png
Total deaths over time
World map of total confirmed COVID-19 cases per million people.png
Total confirmed cases of COVID-19 per million people [303]
Total-covid-deaths-per-million.png
Total confirmed deaths due to COVID-19 per million people (spring 2020) [304]

Infection fatality rate

Infection fatality rate or infection fatality ratio (IFR) is distinguished from case fatality rate (CFR). The CFR for a disease is the proportion of deaths from the disease compared to the total number of people diagnosed with the disease (within a certain period of time). The IFR, in contrast, is the proportion of deaths among all the infected individuals. IFR, unlike CFR, attempts to account for all asymptomatic and undiagnosed infections.

In February, the World Health Organization reported estimates of IFR between 0.3% and 1%. [305] [306] On 2 July, The WHO's Chief Scientist reported that the average IFR estimate presented at a two-day WHO expert forum was about 0.6%. [307] [308]

The CDC estimated for planning purposes that the IFR was 0.65% and that 40% of infected individuals are asymptomatic, suggesting a fatality rate among those who are symptomatic of 1.1% (.65/60) (as of 10 July). [309] [310] Studies incorporating data from broad serology testing in Europe show IFR estimates converging at approximately 0.5–1%. [311] According to the University of Oxford Centre for Evidence-Based Medicine (CEBM), random antibody testing in Germany suggested a national IFR of 0.4% (0.1% to 0.9%). [312] [313] [314]

Firm lower limits of IFRs have been established in a number of locations such as New York City and Bergamo in Italy since the IFR cannot be less than the population fatality rate. As of 10 July, in New York City, with a population of 8.4 million, 23,377 individuals (18,758 confirmed and 4,619 probable) have died with COVID-19 (0.3% of the population). [315] Antibody testing in New York City suggested an IFR of ~0.9%, [316] and ~1.4%. [317] In Bergamo province, 0.6% of the population has died. [318]

Sex differences

Early reviews of epidemiologic data showed greater impact of the pandemic and a higher mortality rate in men in China and Italy. [1] [319] [320] The Chinese Center for Disease Control and Prevention reported the death rate was 2.8% for men and 1.7% for women. [321] Later reviews in June 2020 indicated that there is no significant difference in susceptibility or in CFR between genders. [322] [323] One review acknowledges the different mortality rates in Chinese men, suggesting that it may be attributable to lifestyle choices such as smoking and drinking alcohol rather than genetic factors. [324] Sex-based immunological differences, lesser prevalence of smoking in women and men developing co-morbid conditions such as hypertension at a younger age than women could have contributed to the higher mortality in men. [325] In Europe, 57% of the infected people were men and 72% of those died with COVID-19 were men. [326] As of April 2020, the US government is not tracking sex-related data of COVID-19 infections. [327] Research has shown that viral illnesses like Ebola, HIV, influenza and SARS affect men and women differently. [327]

Ethnic differences

In the US, a greater proportion of deaths due to COVID-19 have occurred among African Americans. [329] Structural factors that prevent African Americans from practicing social distancing include their concentration in crowded substandard housing and in "essential" occupations such as public transit and health care. Greater prevalence of lacking health insurance and care and of underlying conditions such as diabetes, hypertension and heart disease also increase their risk of death. [330] Similar issues affect Native American and Latino communities. [329] According to a US health policy non-profit, 34% of American Indian and Alaska Native People (AIAN) non-elderly adults are at risk of serious illness compared to 21% of white non-elderly adults. [331] The source attributes it to disproportionately high rates of many health conditions that may put them at higher risk as well as living conditions like lack of access to clean water. [332] Leaders have called for efforts to research and address the disparities. [333]

In the U.K., a greater proportion of deaths due to COVID-19 have occurred in those of a Black, Asian, and other ethnic minority background. [334] [335] [336]


Name

During the initial outbreak in Wuhan, China, the virus and disease were commonly referred to as "coronavirus" and "Wuhan coronavirus", [337] [338] [339] with the disease sometimes called "Wuhan pneumonia". [340] [341] In the past, many diseases have been named after geographical locations, such as the Spanish flu, [342] Middle East Respiratory Syndrome, and Zika virus. [343]

In January 2020, the World Health Organization recommended 2019-nCov [344] and 2019-nCoV acute respiratory disease [345] as interim names for the virus and disease per 2015 guidance and international guidelines against using geographical locations (e.g. Wuhan, China), animal species, or groups of people in disease and virus names in part to prevent social stigma. [346] [347] [348]

The official names COVID-19 and SARS-CoV-2 were issued by the WHO on 11 February 2020. [349] WHO chief Tedros Adhanom Ghebreyesus explained: CO for corona, VI for virus, D for disease and 19 for when the outbreak was first identified (31 December 2019). [350] The WHO additionally uses "the COVID-19 virus" and "the virus responsible for COVID-19" in public communications. [349]

Misinformation

After the initial outbreak of COVID-19, misinformation and disinformation regarding the origin, scale, prevention, treatment, and other aspects of the disease rapidly spread online. [351] [352] [353]

Other animals

Humans appear to be capable of spreading the virus to some other animals, a type of disease transmission referred to as zooanthroponosis. A domestic cat in Liège, Belgium, tested positive after it started showing symptoms (diarrhoea, vomiting, shortness of breath) a week later than its owner, who was also positive. [354] Tigers and lions at the Bronx Zoo in New York, United States, tested positive for the virus and showed symptoms of COVID-19, including a dry cough and loss of appetite. [355] Minks at two farms in the Netherlands also tested positive for COVID-19. [356] In Denmark, as of October 31, 2020, 175 mink farms had seen COVID-19 infection in mink, and also USA; Finland, Sweden and Spain have seen infections in mink. [357] [358]

A study on domesticated animals inoculated with the virus found that cats and ferrets appear to be "highly susceptible" to the disease, while dogs appear to be less susceptible, with lower levels of viral replication. The study failed to find evidence of viral replication in pigs, ducks, and chickens. [359]

In March 2020, researchers from the University of Hong Kong have shown that Syrian hamsters could be a model organism for COVID-19 research. [360]

As of August 2020, dozens of domestic cats and dogs had tested positive, though according to the U.S. CDC, there was no evidence they transmitted the virus to humans. [361] CDC guidance recommends potentially infected people avoid close contact with pets. [361]

On 4 November 2020, Prime Minister of Denmark Mette Frederiksen stated that a mutated coronavirus was being transmitted to humans via minks, tied primarily to mink farms in Northern Jutland. [362]

Research

Remdesivir is the only drug that has been approved with a specific indication to treat COVID-19. [363] In Australia and the European Union, remdesivir (Veklury) is indicated for the treatment of COVID-19 in adults and adolescents aged twelve years and older with body weight at least 40 kilograms (88 lb) with pneumonia requiring supplemental oxygen. [364] [365] [366] International research on vaccines and medicines in COVID-19 is underway by government organisations, academic groups, and industry researchers. [367] [368] In March, the World Health Organization initiated the "Solidarity Trial" to assess the treatment effects of four existing antiviral compounds with the most promise of efficacy. [369] The World Health Organization suspended hydroxychloroquine from its global drug trials for COVID-19 treatments on 26 May 2020 due to safety concerns. It had previously enrolled 3,500 patients from 17 countries in the Solidarity Trial. [370] France, Italy and Belgium also banned the use of hydroxychloroquine as a COVID-19 treatment. [371]

Remdesivir was approved for medical use in the United States in October 2020. [372] [373] It is the first treatment for COVID-19 to be approved by the U.S. Food and Drug Administration (FDA). [373] It is indicated for use in adults and adolescents aged twelve years and older with body weight at least 40 kilograms (88 lb) for the treatment of COVID-19 requiring hospitalization. [373]

Modelling research has been conducted with several objectives, including predictions of the dynamics of transmission, [374] diagnosis and prognosis of infection, [375] estimation of the impact of interventions, [376] [377] or allocation of resources. [378] Modelling studies are mostly based on epidemiological models, [379] estimating the number of infected people over time under given conditions. Several other types of models have been developed and used during the COVID-19 including computational fluid dynamics models to study the flow physics of COVID-19, [380] retrofits of crowd movement models to study occupant exposure, [381] mobility-data based models to investigate transmission, [382] or the use of macroeconomic models to assess the economic impact of the pandemic. [383]

There has been a great deal of COVID-19 research, involving accelerated research processes and publishing shortcuts to meet the global demand. [384] To minimise the harm from misinformation, medical professionals and the public are advised to expect rapid changes to available information, and to be attentive to retractions and other updates. [385]

Vaccine

In dark green are the countries that ordered millions of Sputnik V doses. In light green are the countries that have shown interest in obtaining the vaccine. Sputnik V countries.png
In dark green are the countries that ordered millions of Sputnik V doses. In light green are the countries that have shown interest in obtaining the vaccine.
A COVID‑19 vaccine is any of several different vaccine technologies intended to provide acquired immunity against coronavirus disease 2019 (COVID‑19). Previous work to develop a vaccine against the coronavirus diseases SARS and MERS established knowledge about the structure and function of coronaviruses, which accelerated development during early 2020 of varied technology platforms for a COVID‑19 vaccine. [386]
Coalition for Epidemic Preparedness Innovations (CEPI) scientists reported in September 2020, that nine different technology platforms with the technology of numerous candidates remaining undefined were under research and development during 2020, to create an effective vaccine against COVID‑19. [387] According to CEPI, most of the platforms of vaccine candidates in clinical trials as of September are focused on the coronavirus spike protein and its variants as the primary antigen of COVID‑19 infection. [387] Platforms being developed in 2020, involve nucleic acid technologies (RNA and DNA), non-replicating viral vectors, peptides, recombinant proteins, live attenuated viruses, and inactivated viruses. [386] [387] [388] [389]

Medications

At least 29 Phase II–IV efficacy trials in COVID-19 were concluded in March 2020, or scheduled to provide results in April from hospitals in China. [390] [391] There are more than 300 active clinical trials underway as of April 2020. [102] Seven trials were evaluating already approved treatments, including four studies on hydroxychloroquine or chloroquine. [391] Repurposed antiviral drugs make up most of the research, with nine Phase III trials on remdesivir across several countries due to report by the end of April. [390] [391] Other candidates in trials include vasodilators, corticosteroids, immune therapies, lipoic acid, bevacizumab, and recombinant angiotensin-converting enzyme 2. [391]

The COVID-19 Clinical Research Coalition has goals to 1) facilitate rapid reviews of clinical trial proposals by ethics committees and national regulatory agencies, 2) fast-track approvals for the candidate therapeutic compounds, 3) ensure standardised and rapid analysis of emerging efficacy and safety data and 4) facilitate sharing of clinical trial outcomes before publication. [392] [393]

Several existing medications are being evaluated for the treatment of COVID-19, [363] including remdesivir, chloroquine, hydroxychloroquine, lopinavir/ritonavir, and lopinavir/ritonavir combined with interferon beta. [369] [394] There is tentative evidence for efficacy by remdesivir, and on 1 May 2020, the United States Food and Drug Administration (FDA) gave the drug an emergency use authorization (EUA) for people hospitalized with severe COVID-19. [395] On 28 August 2020, the FDA broadened the EUA for remdesivir to include all hospitalized patients with suspected or laboratory-confirmed COVID-19, irrespective of the severity of their disease. [396] Phase III clinical trials for several drugs[ which? ] are underway[ when? ] in several countries, including the US, China, and Italy. [363] [390] [397]

There are mixed results as of 3 April 2020, as to the effectiveness of hydroxychloroquine as a treatment for COVID-19, with some studies showing little or no improvement. [398] [399] One study has shown an association between hydroxychloroquine or chloroquine use with higher death rates along with other side effects. [400] [401] A retraction of this study by its authors was published by The Lancet on 4 June 2020. [402] The studies of chloroquine and hydroxychloroquine with or without azithromycin have major limitations that have prevented the medical community from embracing these therapies without further study. [102] On 15 June 2020, the FDA updated the fact sheets for the emergency use authorization of remdesivir to warn that using chloroquine or hydroxychloroquine with remdesivir may reduce the antiviral activity of remdesivir. [403]

In June, initial results from a randomised trial in the United Kingdom showed that dexamethasone reduced mortality by one third for patients who are critically ill on ventilators and one fifth for those receiving supplemental oxygen. [404] Because this is a well tested and widely available treatment this was welcomed by the WHO that is in the process of updating treatment guidelines to include dexamethasone or other steroids. [405] [406] Based on those preliminary results, dexamethasone treatment has been recommended by the National Institutes of Health for patients with COVID-19 who are mechanically ventilated or who require supplemental oxygen but not in patients with COVID-19 who do not require supplemental oxygen. [407]

In September 2020, the WHO released updated guidance on using corticosteroids for COVID-19. [408] The WHO recommends systemic corticosteroids rather than no systemic corticosteroids for the treatment of people with severe and critical COVID-19 (strong recommendation, based on moderate certainty evidence). [408] The WHO suggests not to use corticosteroids in the treatment of people with non-severe COVID-19 (conditional recommendation, based on low certainty evidence). [408] The updated guidance was based on a meta-analysis of clinical trials of critically ill COVID-19 patients. [409] [410]

In September 2020, the European Medicines Agency (EMA) endorsed the use of dexamethasone in adults and adolescents from twelve years of age and weighing at least 40 kilograms (88 lb) who require supplemental oxygen therapy. [411] Dexamethasone can be taken by mouth or given as an injection or infusion (drip) into a vein. [411]

In November 2020, a US National Institutes of Health clinical trial evaluating the safety and effectiveness of hydroxychloroquine for the treatment of adults with coronavirus disease 2019 (COVID-19) has formally concluded that the drug provides no clinical benefit to hospitalized patients. [412]

In November 2020, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID-19. [413] Bamlanivimab is authorized for people with positive results of direct SARS-CoV-2 viral testing who are twelve years of age and older weighing at least 40 kilograms (88 lb), and who are at high risk for progressing to severe COVID-19 or hospitalization. [413] This includes those who are 65 years of age or older, or who have certain chronic medical conditions. [413]

Cytokine storm

A cytokine storm can be a complication in the later stages of severe COVID-19.

Tocilizumab has been included in treatment guidelines by China's National Health Commission after a small study was completed. [414] [415] It is undergoing a Phase II non-randomised trial at the national level in Italy after showing positive results in people with severe disease. [416] [417] Combined with a serum ferritin blood test to identify a cytokine storm (also called cytokine storm syndrome, not to be confused with cytokine release syndrome), it is meant to counter such developments, which are thought to be the cause of death in some affected people. [418] The interleukin-6 receptor antagonist was approved by the Food and Drug Administration (FDA) to undergo a Phase III clinical trial assessing its effectiveness on COVID-19 based on retrospective case studies for the treatment of steroid-refractory cytokine release syndrome induced by a different cause, CAR T cell therapy, in 2017. [419] To date,[ when? ] there is no randomised, controlled evidence that tocilizumab is an efficacious treatment for CRS. Prophylactic tocilizumab has been shown to increase serum IL-6 levels by saturating the IL-6R, driving IL-6 across the blood-brain barrier, and exacerbating neurotoxicity while having no effect on the incidence of CRS. [420]

Lenzilumab, an anti-GM-CSF monoclonal antibody, is protective in murine models for CAR T cell-induced CRS and neurotoxicity and is a viable therapeutic option due to the observed increase of pathogenic GM-CSF secreting T-cells in hospitalised patients with COVID-19. [421]

The Feinstein Institute of Northwell Health announced in March a study on "a human antibody that may prevent the activity" of IL-6. [422]

Passive antibodies

Transferring purified and concentrated antibodies produced by the immune systems of those who have recovered from COVID-19 to people who need them is being investigated as a non-vaccine method of passive immunisation. [423] [424] Viral neutralization is the anticipated mechanism of action by which passive antibody therapy can mediate defence against SARS-CoV-2. The spike protein of SARS-CoV-2 is the primary target for neutralizing antibodies. [425] As of 8 August 2020, eight neutralizing antibodies targeting the spike protein of SARS-CoV-2 have entered clinical studies. [426] It has been proposed that selection of broad-neutralizing antibodies against SARS-CoV-2 and SARS-CoV might be useful for treating not only COVID-19 but also future SARS-related CoV infections. [425] Other mechanisms, however, such as antibody-dependent cellular cytotoxicity and/or phagocytosis, may be possible. [423] Other forms of passive antibody therapy, for example, using manufactured monoclonal antibodies, are in development. [423]

The use of passive antibodies to treat people with active COVID-19 is also being studied. This involves the production of convalescent serum, which consists of the liquid portion of the blood from recovered patients and contains antibodies specific to this virus, which is then administered to current patients. [423] This strategy was tried for SARS with inconclusive results. [423] A Cochrane review in October 2020 found insufficient evidence to recommend for or against this treatment in COVID-19, due in large part to the methodology of the clinical trials conducted so far. [424] Specifically, there are no trials yet conducted for which the safety of convalescent serum administration to people with COVID-19 can be determined, and the differing outcomes measured in different studies limits their use in determining efficacy. [424]

Laminoid antibodies

Peru announced in April 2020, that it would begin working toward creating a vaccine, with the pharmaceutical company Farvet and Universidad Peruana Cayetano Heredia (UPCH) announcing plans to jointly develop a vaccine in Chincha. [427] Peru's Experimental Station for Scientific Research and Genetic Improvement of Alpacas belonging to the Inca Group, selected on 5 June 2020 four alpacas for the development of a new vaccine that it had been developing in conjunction with Farvet and UPCH. They also indicated that alpacas have the ability to generate some types of antibodies known as "nanobodies", which are very small and have a greater potential to treat pathogens. [428] According to Andina, research from the United States, Belgium, and Chile showed that antibodies from laminoid animals could possibly be formulated into inhaler or injection treatments for those infected with coronaviruses, with Teodosio Huanca of Peru's National Institute of Agricultural Innovation (INIA) National Camelid Program stating that Peruvian camelidae share the same genetic roots and antibodies. [429]

On 7 August, the Peruvian National Institute of Health (INS) announced that it would begin the development of a possible treatment for COVID-19 using "recombinant nanoantibodies" from a llama named "Tito". [430] According to the INIA, Peru holds "the only germplasm bank of South American camelids in the world, with 1,700 samples of alpacas and 1,200 of llamas". [430]

BCG vaccine

Researchers have studied the BCG vaccine for potential non-specific protection against COVID-19 after observing that mortality and severity of disease has been lower in developing countries. The WHO cautions that there are many factors that could impact these observations such as testing rate and disease burden. [431] In randomised controlled trials BCG has shown non-specific protection against other respiratory infections. [432]

There is currently not enough evidence to support a conclusion that BCG vaccine is effective to protect against COVID-19. [433] The University of Exeter announced the BRACE trial, a large international trial to study whether BCG vaccination reduces the impact of COVID-19 in healthcare workers. [434] [435] A similar study was announced in the Netherlands. [432]

See also

Notes

  1. Known as "close contact" which is variously defined, including within ~1.8 metres (six feet) by the US Centers for Disease Control and Prevention (CDC), and being face to face for a cumulative total of 15 minutes, [17] or either 15 minutes of face to face proximity or sharing an enclosed space for a prolonged period such as two hours by the Australian Health Department. [18] [19]

Related Research Articles

Severe acute respiratory syndrome Disease caused by severe acute respiratory syndrome coronavirus

Severe acute respiratory syndrome (SARS) is a viral respiratory disease of zoonotic origin caused by severe acute respiratory syndrome coronavirus, the first identified strain of the SARS coronavirus species Severe acute respiratory syndrome–related coronavirus (SARSr-CoV). The syndrome caused the 2002–2004 SARS outbreak. In late 2017, Chinese scientists traced the virus through the intermediary of Asian palm civets to cave-dwelling horseshoe bats in Yunnan.

Viral pneumonia is a pneumonia caused by a virus. Viruses are one of the two major causes of pneumonia, the other being bacteria; less common causes are fungi and parasites. Viruses are the most common cause of pneumonia in children, while in adults bacteria are a more common cause.

Severe acute respiratory syndrome coronavirus Virus strain causing severe acute respiratory syndrome

Severe acute respiratory syndrome coronavirus is a strain of virus that causes severe acute respiratory syndrome (SARS). It is an enveloped, positive-sense, single-stranded RNA virus which infects the epithelial cells within the lungs. The virus enters the host cell by binding to angiotensin-converting enzyme 2. It infects humans, bats, and palm civets.

<i>Human coronavirus NL63</i> Species of virus

Human coronavirus NL63 (HCoV-NL63) is a species of coronavirus, specifically a Setracovirus from among the Alphacoronavirus genus. It was identified in late 2004 in a seven-month-old child with bronchiolitis in the Netherlands. The virus is an enveloped, positive-sense, single-stranded RNA virus which enters its host cell by binding to ACE2. Infection with the virus has been confirmed worldwide, and has an association with many common symptoms and diseases. Associated diseases include mild to moderate upper respiratory tract infections, severe lower respiratory tract infection, croup and bronchiolitis.

W. Ian Lipkin Professor, microbiologist, epidemiologist

W. Ian Lipkin is the John Snow Professor of Epidemiology at the Mailman School of Public Health at Columbia University and a professor of Neurology and Pathology at the College of Physicians and Surgeons at Columbia University. Lipkin is also director of the Center for Infection and Immunity, an academic laboratory for microbe hunting in acute and chronic diseases.

Middle East respiratory syndrome Viral respiratory infection

Middle East respiratory syndrome (MERS), also known as camel flu, is a viral respiratory infection caused by the MERS-coronavirus (MERS-CoV). Symptoms may range from none, to mild, to severe. Typical symptoms include fever, cough, diarrhea, and shortness of breath. The disease is typically more severe in those with other health problems.

COVID-19 pandemic Ongoing pandemic of coronavirus disease 2019

The COVID-19 pandemic, also known as the coronavirus pandemic, is an ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first identified in December 2019 in Wuhan, China. The World Health Organization declared the outbreak a Public Health Emergency of International Concern in January 2020 and a pandemic in March 2020. As of 29 November 2020, more than 62.6 million cases have been confirmed, with more than 1.45 million deaths attributed to COVID-19.

Severe acute respiratory syndrome coronavirus 2 Virus strain that causes coronavirus disease 2019 (COVID-19)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic. Colloquially known as simply the coronavirus, it was previously referred to by its provisional name, 2019 novel coronavirus (2019-nCoV), and has also been called human coronavirus 2019. The World Health Organization declared the outbreak a Public Health Emergency of International Concern on 30 January 2020, and a pandemic on 11 March 2020.

COVID-19 testing Diagnostic testing for SARS-CoV-2 virus infection

COVID-19 testing involves analyzing samples to assess the current or past presence of SARS-CoV-2. The two main branches detect either the presence of the virus or of antibodies produced in response to infection. Tests for viral presence are used to diagnose individual cases and to allow public health authorities to trace and contain outbreaks. Antibody tests instead show whether someone once had the disease. They are less useful for diagnosing current infections because antibodies may not develop for weeks after infection. It is used to assess disease prevalence, which aids the estimation of the infection fatality rate.

COVID-19 drug repurposing research Drug repurposing research related to COVID-19

Drug repositioning is the re-purposing of an approved drug for the treatment of a different disease or medical condition than that for which it was originally developed. This is one line of scientific research which is being pursued to develop safe and effective COVID-19 treatments. Other research directions include the development of a COVID-19 vaccine and convalescent plasma transfusion.

COVID-19 drug development Preventative and therapeutic medications for COVID-19 infection

COVID‑19 drug development is the research process to develop preventative therapeutic prescription drugs that would alleviate the severity of coronavirus disease 2019 (COVID‑19). Internationally by November 2020, several hundred drug companies, biotechnology firms, university research groups, and health organizations were developing over 500 potential therapies for COVID‑19 disease in various stages of preclinical or clinical research.

COVID-19 surveillance

COVID-19 surveillance involves monitoring the spread of the coronavirus disease in order to establish the patterns of disease progression. The World Health Organization (WHO) recommends active surveillance, with focus of case finding, testing and contact tracing in all transmission scenarios. COVID-19 surveillance is expected to monitor epidemiological trends, rapidly detect new cases, and based on this information, provide epidemiological information to conduct risk assessment and guide disease preparedness.

Allison McGeer is a Canadian infectious disease specialist in the Sinai Health System, a Professor at the Dalla Lana School of Public Health and a Senior Clinician Scientist at the Lunenfeld-Tanenbaum Research Institute. McGeer has led investigations into the severe acute respiratory syndrome outbreak in Toronto and worked alongside Donald Low. During the COVID-19 pandemic, McGeer has studied how SARS-CoV-2 survives in the air.

Samira Mubareka is a Canadian microbiologist who is a clinical scientist at the Sunnybrook Health Sciences Centre in Toronto, Ontario. Her research considers the influenza virus, viral transmission and aerobiology. During the COVID-19 pandemic Mubareka isolated the genome of Severe Acute Respiratory Syndrome COronaVirus 2 (SARS-CoV-2) in an effort to improve detection and diagnostics.

Carolyn S. Calfee is a Professor of Medicine and Anaesthesia at the University of California, San Francisco. She works in intensive care at the UCSF Medical Center where she specialises in acute respiratory distress syndrome. During the COVID-19 pandemic Calfee studied why SARS-CoV-2 patients experienced such different symptoms.

Timeline of the COVID-19 pandemic in 2019 Sequence of major events in a virus pandemic

This article documents the chronology and epidemiology in 2019 of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19) and is responsible for the COVID-19 pandemic. The first human cases of COVID-19 were identified in Wuhan, China, in December.

Symptoms of COVID-19 Overview of the symptoms of COVID-19

Symptoms of COVID-19 are variable, but usually include fever and a cough. People with the same infection may have different symptoms, and their symptoms may change over time. For example, one person may have a high fever, a cough, and fatigue, and another person may have a low fever at the start of the disease and develop difficulty breathing a week later. However, in people without prior ears, nose, and throat (ENT) disorders, loss of taste combined with loss of smell is associated with COVID-19 with a specificity of 95%.

Multisystem inflammatory syndrome in children Disease of children; pediatric comorbidity from COVID-19

Multisystem inflammatory syndrome in children (MIS-C), or paediatric inflammatory multisystem syndrome, is a rare systemic illness involving persistent fever and extreme inflammation following exposure to SARS-CoV-2, the virus responsible for COVID-19. It can rapidly lead to medical emergencies such as insufficient blood flow around the body. Failure of one or more organs can occur. A warning sign is unexplained persistent fever with severe symptoms following exposure to COVID-19. Prompt referral to paediatric specialists is essential, and families need to seek urgent medical assistance. Most affected children will need intensive care.

The management of COVID-19 includes supportive care, which may include fluid therapy, oxygen support, and supporting other affected vital organs. The WHO is in the process of including dexamethasone in guidelines for treatment for hospitalized patients, and it is recommended for consideration in Australian guidelines for patients requiring oxygen. CDC recommends those who suspect they carry the virus wear a simple face mask. Extracorporeal membrane oxygenation (ECMO) has been used to address the issue of respiratory failure, but its benefits are still under consideration. Personal hygiene and a healthy lifestyle and diet have been recommended to improve immunity. Supportive treatments may be useful in those with mild symptoms at the early stage of infection. Nasal breathing is suggested as such a procedure based on several peer reviewed studies.

Transmission of COVID-19 Mechanisms that spread coronavirus disease 2019

Coronavirus disease 2019 (COVID-19) spreads from person to person mainly through the respiratory route after an infected person coughs, sneezes, sings, talks or breathes. A new infection occurs when virus-containing particles exhaled by an infected person, either respiratory droplets or aerosols, get into the mouth, nose, or eyes of other people who are in close contact with the infected person.

References

  1. 1 2 Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. (February 2020). "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study". Lancet. 395 (10223): 507–513. doi: 10.1016/S0140-6736(20)30211-7 . PMC   7135076 . PMID   32007143.
  2. Han X, Cao Y, Jiang N, Chen Y, Alwalid O, Zhang X, et al. (March 2020). "Novel Coronavirus Pneumonia (COVID-19) Progression Course in 17 Discharged Patients: Comparison of Clinical and Thin-Section CT Features During Recovery". Clinical Infectious Diseases. 71 (15): 723–731. doi: 10.1093/cid/ciaa271 . PMC   7184369 . PMID   32227091.
  3. "Special Act for Prevention, Relief and Revitalization Measures for Severe Pneumonia with Novel Pathogens–Article Content–Laws & Regulations Database of The Republic of China". law.moj.gov.tw. Retrieved 10 May 2020.
  4. "Covid-19" . Oxford English Dictionary (Online ed.). Oxford University Press. April 2020. Retrieved 15 April 2020. (Subscription or participating institution membership required.)
  5. "Symptoms of Coronavirus". U.S. Centers for Disease Control and Prevention (CDC). 13 May 2020. Archived from the original on 17 June 2020. Retrieved 18 June 2020.
  6. "Q&A on coronaviruses (COVID-19)". World Health Organization. 17 April 2020. Archived from the original on 14 May 2020. Retrieved 14 May 2020.
  7. Nussbaumer-Streit B, Mayr V, Dobrescu AI, Chapman A, Persad E, Klerings I, et al. (April 2020). "Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review". The Cochrane Database of Systematic Reviews. 4: CD013574. doi:10.1002/14651858.CD013574. PMC   7141753 . PMID   32267544.
  8. 1 2 3 "COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)". ArcGIS . Johns Hopkins University . Retrieved 30 November 2020.
  9. Ye Q, Wang B, Mao J (June 2020). "The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19". The Journal of Infection. 80 (6): 607–613. doi:10.1016/j.jinf.2020.03.037. PMC   7194613 . PMID   32283152.
  10. Yelin D, Wirtheim E, Vetter P, Kalil AC, Bruchfeld J, Runold M, et al. (September 2020). "Long-term consequences of COVID-19: research needs". The Lancet. Infectious Diseases. 20 (10): 1115–1117. doi:10.1016/S1473-3099(20)30701-5. PMC   7462626 . PMID   32888409.
  11. "What are the long-term symptoms of COVID-19?". HMRI. 4 August 2020. Retrieved 8 September 2020.
  12. "COVID-19 (coronavirus): Long-term effects". Mayo Clinic. 18 August 2020. Retrieved 8 September 2020.
  13. "What are the long-term health risks following COVID-19?". NewsGP. Royal Australian College of General Practitioners (RACGP). 24 June 2020. Retrieved 8 September 2020.
  14. "COVID-19 transmission—up in the air". The Lancet Respiratory Medicine . October 2020. doi: 10.1016/S2213-2600(20)30514-2 .
  15. Karia R, Gupta I, Khandait H, Yandav A, Yandav A (2020). "COVID-19 and its Modes of Transmission". SN Compr Clin Med. 2 (10): 1798–1801. doi: 10.1007/s42399-020-00498-4 . PMC   7461745 . PMID   32904860.
  16. https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions
  17. CDC. "Coronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention. Retrieved 22 October 2020.
  18. "Quarantine for coronavirus (COVID-19)". Australian Government Department of Health. Retrieved 25 September 2020.
  19. "How COVID-19 Spreads". U.S. Centers for Disease Control and Prevention (CDC). 18 September 2020. Archived from the original on 19 September 2020. Retrieved 20 September 2020.
  20. "Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)". U.S. Centers for Disease Control and Prevention (CDC). 6 April 2020. Archived from the original on 2 March 2020. Retrieved 19 April 2020.
  21. Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL, Wade RG (23 June 2020). "The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries". PLOS ONE. 15 (6): e0234765. Bibcode:2020PLoSO..1534765G. doi:10.1371/journal.pone.0234765. PMC   7310678 . PMID   32574165. S2CID   220046286.
  22. "Symptoms of Coronavirus". U.S. Centers for Disease Control and Prevention (CDC). 13 May 2020. Archived from the original on 17 June 2020. Retrieved 18 June 2020.
  23. Bénézit, François; Le Turnier, Paul; Declerck, Charles; Paillé, Cécile; Revest, Matthieu; Dubée, Vincent; Tattevin, Pierre (2020). "Utility of hyposmia and hypogeusia for the diagnosis of COVID-19". The Lancet Infectious Diseases. 20 (9): 1014–1015. doi:10.1016/S1473-3099(20)30297-8. PMC   7159866 . PMID   32304632. S2CID   215769604.
  24. 1 2 Gandhi RT, Lynch JB, Del Rio C (April 2020). "Mild or Moderate Covid-19". The New England Journal of Medicine. 383 (18): 1757–1766. doi: 10.1056/NEJMcp2009249 . PMID   32329974.
  25. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC (August 2020). "Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review". JAMA. 324 (8): 782–793. doi: 10.1001/jama.2020.12839 . PMID   32648899. S2CID   220465311.
  26. Nogrady, Bianca (18 November 2020). "What the data say about asymptomatic COVID infections". Nature. 587 (7835): 534–535. doi:10.1038/d41586-020-03141-3.
  27. 1 2 Gao Z, Xu Y, Sun C, Wang X, Guo Y, Qiu S, Ma K (May 2020). "A Systematic Review of Asymptomatic Infections with COVID-19". Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi. doi: 10.1016/j.jmii.2020.05.001 . PMC   7227597 . PMID   32425996.
  28. Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. (June 2020). "Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths". Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi. 53 (3): 404–412. doi:10.1016/j.jmii.2020.02.012. PMC   7128959 . PMID   32173241.
  29. Furukawa NW, Brooks JT, Sobel J (July 2020). "Evidence Supporting Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic". Emerging Infectious Diseases. 26 (7). doi: 10.3201/eid2607.201595 . PMC   7323549 . PMID   32364890.
  30. Furukawa, Nathan W.; Brooks, John T.; Sobel, Jeremy (4 May 2020). "Evidence Supporting Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic". Emerging Infectious Diseases. 26 (7). doi:10.3201/eid2607.201595. PMC   7323549 . PMID   32364890 . Retrieved 29 September 2020.
  31. "Q&A: How is COVID-19 transmitted? (How is the virus that causes COVID-19 most commonly transmitted between people?)". www.who.int . 9 July 2020. Retrieved 14 October 2020.
  32. 1 2 "Transmission of COVID-19". www.ecdc.europa.eu . 7 September 2020. Retrieved 14 October 2020.
  33. "Q & A on COVID-19: Basic facts". www.ecdc.europa.eu . 25 September 2020. Retrieved 8 October 2020.
  34. "How COVID-19 Spreads". www.cdc.gov . 5 October 2020. Retrieved 7 October 2020.
  35. "Outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): increased transmission beyond China – fourth update" (PDF). European Centre for Disease Prevention and Control. 14 February 2020. Retrieved 8 March 2020.
  36. 1 2 Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF (April 2020). "The proximal origin of SARS-CoV-2". Nature Medicine. 26 (4): 450–452. doi:10.1038/s41591-020-0820-9. PMC   7095063 . PMID   32284615.
  37. Gibbens S (18 March 2020). "Why soap is preferable to bleach in the fight against coronavirus". National Geographic . Archived from the original on 2 April 2020. Retrieved 2 April 2020.
  38. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. (February 2020). "A Novel Coronavirus from Patients with Pneumonia in China, 2019". New England Journal of Medicine. 382 (8): 727–733. doi:10.1056/NEJMoa2001017. PMC   7092803 . PMID   31978945.
  39. 1 2 3 Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) (PDF) (Report). World Health Organization (WHO). 24 February 2020. Archived (PDF) from the original on 29 February 2020. Retrieved 21 March 2020.
  40. Rathore JS, Ghosh C (August 2020). "Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a newly emerged pathogen: an overview". Pathogens and Disease . 78 (6). doi: 10.1093/femspd/ftaa042 . ISSN   2049-632X. OCLC   823140442. PMC   7499575 . PMID   32840560.
  41. Thomas S (2020). "The Structure of the Membrane Protein of SARS-CoV-2 Resembles the Sugar Transporter SemiSWEET". Pathogens and Immunity. 5 (1): 342–363. doi: 10.20411/pai.v5i1.377 . PMC   7608487 . PMID   33154981. S2CID   226246581.
  42. "Coronavirus and COVID-19: What You Should Know". WebMD . Retrieved 31 July 2020.
  43. Verdecchia P, Cavallini C, Spanevello A, Angeli F (June 2020). "The pivotal link between ACE2 deficiency and SARS-CoV-2 infection". European Journal of Internal Medicine. 76: 14–20. doi:10.1016/j.ejim.2020.04.037. PMC   7167588 . PMID   32336612.
  44. Letko M, Marzi A, Munster V (April 2020). "Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses". Nature Microbiology. 5 (4): 562–569. doi: 10.1038/s41564-020-0688-y . PMC   7095430 . PMID   32094589.
  45. Rodríguez‐Puertas, Rafael (2 September 2020). "ACE2 activators for the treatment of COVID 19 patients". Journal of Medical Virology. 92 (10): 1701–1702. doi:10.1002/jmv.25992. PMC   7267413 . PMID   32379346.
  46. Gurwitz D (March 2020). "Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics". Drug Development Research. 81 (5): 537–540. doi: 10.1002/ddr.21656 . PMC   7228359 . PMID   32129518.
  47. Gibson PG, Qin L, Puah SH (April 2020). "COVID‐19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre‐COVID‐19 ARDS". The Medical Journal of Australia. 213 (2): 54–56.e1. doi:10.5694/mja2.50674. PMC   7361309 . PMID   32572965.
  48. 1 2 Pezzini A, Padovani A (November 2020). "Lifting the mask on neurological manifestations of COVID-19". Nature Reviews. Neurology. 16 (11): 636–644. doi:10.1038/s41582-020-0398-3. PMC   7444680 . PMID   32839585.
  49. Li YC, Bai WZ, Hashikawa T (February 2020). "The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients". Journal of Medical Virology. 92 (6): 552–555. doi: 10.1002/jmv.25728 . PMC   7228394 . PMID   32104915.
  50. Baig AM, Khaleeq A, Ali U, Syeda H (April 2020). "Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms". ACS Chemical Neuroscience. 11 (7): 995–998. doi:10.1021/acschemneuro.0c00122. PMC   7094171 . PMID   32167747.
  51. Yavarpour-Bali H, Ghasemi-Kasman M (1 September 2020). "Update on neurological manifestations of COVID-19". Life Sciences. 257: 118063. doi:10.1016/j.lfs.2020.118063. PMC   7346808 . PMID   32652139.
  52. Gu J, Han B, Wang J (May 2020). "COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission". Gastroenterology. 158 (6): 1518–1519. doi:10.1053/j.gastro.2020.02.054. PMC   7130192 . PMID   32142785.
  53. Zhang H, Li H, Lyu J, Lei X, Li W, Wu G, Lyu J, Dai Z (2020). "Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infection". International Journal of Infectious Diseases. Elsevier BV. 96: 19–24. doi:10.1016/j.ijid.2020.04.027. ISSN   1201-9712. PMC   7165079 . PMID   32311451.
  54. 1 2 3 Zheng YY, Ma YT, Zhang JY, Xie X (May 2020). "COVID-19 and the cardiovascular system". Nature Reviews. Cardiology. 17 (5): 259–260. doi:10.1038/s41569-020-0360-5. PMC   7095524 . PMID   32139904.
  55. 1 2 3 Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. (24 January 2020). "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China". Lancet. 395 (10223): 497–506. doi: 10.1016/S0140-6736(20)30183-5 . PMC   7159299 . PMID   31986264.
  56. "Coronavirus disease 2019 (COVID-19): Myocardial infarction and other coronary artery disease issues". UpToDate. Retrieved 28 September 2020.
  57. Turner AJ, Hiscox JA, Hooper NM (June 2004). "ACE2: from vasopeptidase to SARS virus receptor". Trends in Pharmacological Sciences. 25 (6): 291–4. doi: 10.1016/j.tips.2004.04.001 . PMC   7119032 . PMID   15165741.
  58. Abou-Ismail, Mouhamed Yazan; Diamond, Akiva; Kapoor, Sargam; Arafah, Yasmin; Nayak, Lalitha (2 June 2020). "The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management". Thrombosis Research. Elsevier BV. 194: 101–115. doi:10.1016/j.thromres.2020.06.029. ISSN   0049-3848. PMC   7305763 . PMID   32788101.
  59. 1 2 Wadman M (April 2020). "How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes". Science. doi: 10.1126/science.abc3208 .
  60. Coronavirus: Kidney Damage Caused by COVID-19, Johns Hopkins Medicine, C. John Sperati, updated 14 May 2020.
  61. 1 2 3 Eketunde AO, Mellacheruvu Sp, Oreoluwa P (2 July 2020). "A Review of Postmortem Findings in Patients With COVID-19". Cureus. Cureus, Inc. 12 (7): e9438. doi: 10.7759/cureus.9438 . ISSN   2168-8184. PMC   7451084 . PMID   32864262. S2CID   221352704.
  62. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ (March 2020). "The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality". International Journal of Antimicrobial Agents. 55 (5): 105954. doi:10.1016/j.ijantimicag.2020.105954. PMC   7118634 . PMID   32234467.
  63. Gómez-Rial, Jose; Rivero-Calle, Irene; Salas, Antonio; Martinón-Torres, Federico (2020). "Role of Monocytes/Macrophages in Covid-19 Pathogenesis: Implications for Therapy". Infection and Drug Resistance. 13: 2485–2493. doi: 10.2147/IDR.S258639 . PMC   7383015 . PMID   32801787.
  64. "CDC Tests for 2019-nCoV". U.S. Centers for Disease Control and Prevention . 5 February 2020. Archived from the original on 14 February 2020. Retrieved 12 February 2020.
  65. "Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases". World Health Organization (WHO). Archived from the original on 17 March 2020. Retrieved 13 March 2020.
  66. "2019 Novel Coronavirus (2019-nCoV) Situation Summary". U.S. Centers for Disease Control and Prevention (CDC). 30 January 2020. Archived from the original on 26 January 2020. Retrieved 30 January 2020.
  67. "Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19)". U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020. Archived from the original on 4 March 2020. Retrieved 26 March 2020.
  68. "Real-Time RT-PCR Panel for Detection 2019-nCoV". U.S. Centers for Disease Control and Prevention (CDC). 29 January 2020. Archived from the original on 30 January 2020. Retrieved 1 February 2020.
  69. "Curetis Group Company Ares Genetics and BGI Group Collaborate to Offer Next-Generation Sequencing and PCR-based Coronavirus (2019-nCoV) Testing in Europe". GlobeNewswire News Room. 30 January 2020. Archived from the original on 31 January 2020. Retrieved 1 February 2020.
  70. Brueck H (30 January 2020). "There's only one way to know if you have the coronavirus, and it involves machines full of spit and mucus". Business Insider. Archived from the original on 1 February 2020. Retrieved 1 February 2020.
  71. "Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases". Archived from the original on 21 February 2020. Retrieved 26 February 2020.
  72. 1 2 Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. (February 2020). "The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health – The latest 2019 novel coronavirus outbreak in Wuhan, China". International Journal of Infectious Diseases. 91: 264–266. doi: 10.1016/j.ijid.2020.01.009 . PMC   7128332 . PMID   31953166.
  73. Cohen J, Normile D (January 2020). "New SARS-like virus in China triggers alarm" (PDF). Science. 367 (6475): 234–235. Bibcode:2020Sci...367..234C. doi:10.1126/science.367.6475.234. PMID   31949058. S2CID   210701594. Archived (PDF) from the original on 11 February 2020. Retrieved 11 February 2020.
  74. "Severe acute respiratory syndrome coronavirus 2 data hub". NCBI. Archived from the original on 21 March 2020. Retrieved 4 March 2020.
  75. Petherick A (April 2020). "Developing antibody tests for SARS-CoV-2". Lancet. 395 (10230): 1101–1102. doi: 10.1016/s0140-6736(20)30788-1 . PMC   7270070 . PMID   32247384.
  76. Vogel G (March 2020). "New blood tests for antibodies could show true scale of coronavirus pandemic". Science. doi: 10.1126/science.abb8028 .
  77. Pang J, Wang MX, Ang IY, Tan SH, Lewis RF, Chen JI, et al. (February 2020). "Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review". Journal of Clinical Medicine. 9 (3): 623. doi: 10.3390/jcm9030623 . PMC   7141113 . PMID   32110875.
  78. Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, et al. (June 2020). "Antibody tests for identification of current and past infection with SARS-CoV-2". The Cochrane Database of Systematic Reviews. 6: CD013652. doi:10.1002/14651858.CD013652. PMC   7387103 . PMID   32584464. S2CID   220061130.
  79. AFP News Agency (11 April 2020). "How false negatives are complicating COVID-19 testing". Al Jazeera website Retrieved 12 April 2020.
  80. "Coronavirus (COVID-19) Update: FDA Issues first Emergency Use Authorization for Point of Care Diagnostic" (Press release). U.S. Food and Drug Administration (FDA). 21 March 2020. Archived from the original on 21 March 2020. Retrieved 22 March 2020.
  81. Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, et al. (July 2020). "Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease". The Cochrane Database of Systematic Reviews. 7: CD013665. doi:10.1002/14651858.CD013665. PMC   7386785 . PMID   32633856. S2CID   220384495.
  82. Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. (August 2020). "Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19". JAMA Internal Medicine. 180 (8): 1081–1089. doi:10.1001/jamainternmed.2020.2033. PMC   7218676 . PMID   32396163.
  83. Levenfus I, Ullmann E, Battegay E, Schuurmans MM (August 2020). "Triage tool for suspected COVID-19 patients in the emergency room: AIFELL score". The Brazilian Journal of Infectious Diseases. 24 (5): 458–461. doi:10.1016/j.bjid.2020.07.003. PMC   7440000 . PMID   32828735.
  84. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. (February 2020). "A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)". Military Medical Research. 7 (1): 4. doi: 10.1186/s40779-020-0233-6 . PMC   7003341 . PMID   32029004.
  85. To KK, Tsang OT, Chik-Yan Yip C, Chan KH, Wu TC, Chan JM, et al. (February 2020). "Consistent detection of 2019 novel coronavirus in saliva". Clinical Infectious Diseases. Oxford University Press. 71 (15): 841–843. doi:10.1093/cid/ciaa149. PMC   7108139 . PMID   32047895.
  86. 1 2 3 Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A (March 2020). "Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients". AJR. American Journal of Roentgenology. 215 (1): 87–93. doi: 10.2214/AJR.20.23034 . PMID   32174129.
  87. "ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection". American College of Radiology. 22 March 2020. Archived from the original on 28 March 2020.
  88. Pormohammad A, Ghorbani S, Khatami A, Razizadeh MH, Alborzi E, Zarei M, et al. (October 2020). "Comparison of influenza type A and B with COVID-19: A global systematic review and meta-analysis on clinical, laboratory and radiographic findings". Reviews in Medical Virology: e2179. doi: 10.1002/rmv.2179 . PMC   7646051 . PMID   33035373. S2CID   222255245.
  89. Lee EY, Ng MY, Khong PL (April 2020). "COVID-19 pneumonia: what has CT taught us?". The Lancet. Infectious Diseases. 20 (4): 384–385. doi: 10.1016/S1473-3099(20)30134-1 . PMC   7128449 . PMID   32105641.
  90. "ICD-10 Version:2019". World Health Organization . 2019. Archived from the original on 31 March 2020. Retrieved 31 March 2020. U07.2 – COVID-19, virus not identified – COVID-19 NOS – Use this code when COVID-19 is diagnosed clinically or epidemiologically but laboratory testing is inconclusive or not available. Use additional code, if desired, to identify pneumonia or other manifestations
  91. Giani M, Seminati D, Lucchini A, Foti G, Pagni F (May 2020). "Exuberant Plasmocytosis in Bronchoalveolar Lavage Specimen of the First Patient Requiring Extracorporeal Membrane Oxygenation for SARS-CoV-2 in Europe". Journal of Thoracic Oncology. 15 (5): e65–e66. doi:10.1016/j.jtho.2020.03.008. PMC   7118681 . PMID   32194247.
  92. Lillicrap D (April 2020). "Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia". Journal of Thrombosis and Haemostasis. 18 (4): 786–787. doi:10.1111/jth.14781. PMC   7166410 . PMID   32212240.
  93. Mitra A, Dwyre DM, Schivo M, Thompson GR, Cohen SH, Ku N, Graff JP (March 2020). "Leukoerythroblastic reaction in a patient with COVID-19 infection". American Journal of Hematology. 95 (8): 999–1000. doi: 10.1002/ajh.25793 . PMC   7228283 . PMID   32212392.
  94. Maier BF, Brockmann D (May 2020). "Effective containment explains subexponential growth in recent confirmed COVID-19 cases in China". Science. 368 (6492): 742–746. Bibcode:2020Sci...368..742M. doi: 10.1126/science.abb4557 . PMC   7164388 . PMID   32269067. ("...initial exponential growth expected for an unconstrained outbreak.")
  95. Wiles S (9 March 2020). "The three phases of Covid-19 – and how we can make it manageable". The Spinoff. Archived from the original on 27 March 2020. Retrieved 9 March 2020.
  96. 1 2 3 4 Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD (March 2020). "How will country-based mitigation measures influence the course of the COVID-19 epidemic?". Lancet. 395 (10228): 931–934. doi: 10.1016/S0140-6736(20)30567-5 . PMC   7158572 . PMID   32164834. A key issue for epidemiologists is helping policy makers decide the main objectives of mitigation—e.g. minimising morbidity and associated mortality, avoiding an epidemic peak that overwhelms health-care services, keeping the effects on the economy within manageable levels, and flattening the epidemic curve to wait for vaccine development and manufacture on scale and antiviral drug therapies.
  97. Barclay E (10 March 2020). "How canceled events and self-quarantines save lives, in one chart". Vox. Archived from the original on 12 March 2020. Retrieved 12 March 2020.
  98. Barclay E, Scott D, Animashaun A (7 April 2020). "The US doesn't just need to flatten the curve. It needs to "raise the line."". Vox. Archived from the original on 7 April 2020.
  99. 1 2 Wiles S (14 March 2020). "After 'Flatten the Curve', we must now 'Stop the Spread'. Here's what that means". The Spinoff. Archived from the original on 26 March 2020. Retrieved 13 March 2020.
  100. Grenfell R, Drew T (17 February 2020). "Here's Why It's Taking So Long to Develop a Vaccine for the New Coronavirus". Science Alert. Archived from the original on 28 February 2020. Retrieved 26 February 2020.
  101. "COVID-19 Treatment Guidelines". www.nih.gov. National Institutes of Health. Retrieved 21 April 2020.
  102. 1 2 3 4 Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB (April 2020). "Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review". JAMA. 323 (18): 1824–1836. doi: 10.1001/jama.2020.6019 . PMID   32282022.
  103. "Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission". U.S. Centers for Disease Control and Prevention (CDC). 28 June 2020.
  104. 1 2 3 Centers for Disease Control and Prevention (3 February 2020). "Coronavirus Disease 2019 (COVID-19): Prevention & Treatment". Archived from the original on 15 December 2019. Retrieved 10 February 2020.
  105. World Health Organization. "Advice for Public". Archived from the original on 26 January 2020. Retrieved 10 February 2020.
  106. "My Hand-Washing Song: Readers Offer Lyrics For A 20-Second Scrub". NPR.org. Archived from the original on 20 March 2020. Retrieved 20 March 2020.
  107. "Scientific Brief: SARS-CoV-2 and Potential Airborne Transmission". COVID-19 Published Science and Research. Centers for Disease Control and Prevention. Retrieved 30 October 2020.
  108. Centers for Disease Control and Prevention (5 April 2020). "What to Do if You Are Sick". U.S. Centers for Disease Control and Prevention (CDC). Archived from the original on 14 February 2020. Retrieved 24 April 2020.
  109. "Coronavirus Disease 2019 (COVID-19) – Prevention & Treatment". U.S. Centers for Disease Control and Prevention (CDC). 10 March 2020. Archived from the original on 11 March 2020. Retrieved 11 March 2020.
  110. 1 2 3 4 Verbeek JH, Rajamaki B, Ijaz S, Sauni R, Toomey E, Blackwood B, et al. (May 2020). "Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff". The Cochrane Database of Systematic Reviews. 5: CD011621. doi: 10.1002/14651858.CD011621.pub5 . PMID   32412096.
  111. "Wear masks in public says WHO, in update of COVID-19 advice". Reuters. 5 June 2020. Retrieved 3 July 2020.
  112. 1 2 3 "Recommendations for Cloth Face Covers". U.S. Centers for Disease Control and Prevention (CDC). 3 April 2020. Retrieved 3 June 2020.
  113. "When and how to use masks". WHO. Retrieved 3 July 2020.
  114. 1 2 3 4 "Social distancing: what you need to do – Coronavirus (COVID-19)". nhs.uk. 2 June 2020. Retrieved 18 August 2020.
  115. "COVID-19: Use of masks in the community". Ministry of Health NZ. Retrieved 18 August 2020.
  116. 1 2 "Using face masks in the community – Technical Report" (PDF). ECDC. 8 April 2020.
  117. "Which countries have made wearing face masks compulsory?". Al Jazeera. 20 May 2020.
  118. "Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission". U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020. Retrieved 17 April 2020.
  119. "For different groups of people: how to choose masks". NHC.gov.cn. National Health Commission of the People's Republic of China. 7 February 2020. Retrieved 22 March 2020. Disposable medical masks: Recommended for: • People in crowded places • Indoor working environment with a relatively dense population • People going to medical institutions • Children in kindergarten and students at school gathering to study and do other activities
  120. Greenhalgh T, Schmid MB, Czypionka T, Bassler D, Gruer L (April 2020). "Face masks for the public during the covid-19 crisis". BMJ. 369: m1435. doi: 10.1136/bmj.m1435 . PMID   32273267. S2CID   215516381.
  121. "Caring for Someone Sick at Home". U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020. Retrieved 3 July 2020.
  122. Maragakis LL. "Coronavirus, Social Distancing and Self Quarantine". www.hopkinsmedicine.org. Johns Hopkins University. Archived from the original on 18 March 2020. Retrieved 18 March 2020.
  123. Parker-Pope T (19 March 2020). "Deciding How Much Distance You Should Keep". The New York Times . ISSN   0362-4331. Archived from the original on 20 March 2020. Retrieved 20 March 2020.
  124. Systrom K, Krieger M, O'Rourke R, Stein R, Dellaert F, Lerer A (11 April 2020). "Rt Covid-19". rt.live. Retrieved 19 April 2020. Based on Bettencourt LM, Ribeiro RM (May 2008). "Real time bayesian estimation of the epidemic potential of emerging infectious diseases". PLOS ONE. 3 (5): e2185. Bibcode:2008PLoSO...3.2185B. doi:10.1371/journal.pone.0002185. PMC   2366072 . PMID   18478118.
  125. 1 2 "Advice for the public on COVID-19 – World Health Organization". www.who.int. Retrieved 18 August 2020.
  126. "WHO-recommended handrub formulations". WHO Guidelines on Hand Hygiene in Health Care: First Global Patient Safety Challenge Clean Care Is Safer Care. World Health Organization. 19 March 2009. Retrieved 19 March 2020.
  127. "List N: Disinfectants for Use Against SARS-CoV-2 (COVID-19)". US EPA. 13 March 2020.
  128. Fisher D, Heymann D (February 2020). "Q&A: The novel coronavirus outbreak causing COVID-19". BMC Medicine. 18 (1): 57. doi: 10.1186/s12916-020-01533-w . PMC   7047369 . PMID   32106852.
  129. Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. (May 2020). "Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province". Chinese Medical Journal. 133 (9): 1025–1031. doi: 10.1097/CM9.0000000000000744 . PMC   7147277 . PMID   32044814.
  130. Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, Jiang B (March 2020). "Comorbidities and multi-organ injuries in the treatment of COVID-19". Lancet. Elsevier BV. 395 (10228): e52. doi: 10.1016/s0140-6736(20)30558-4 . PMC   7270177 . PMID   32171074.
  131. "Q&A: Dexamethasone and COVID-19". www.who.int. Retrieved 11 July 2020.
  132. "Home". National COVID-19 Clinical Evidence Taskforce. Retrieved 11 July 2020.
  133. Centers for Disease Control and Prevention (5 April 2020). "What to Do if You Are Sick". Centers for Disease Control and Prevention (CDC). Archived from the original on 14 February 2020. Retrieved 24 April 2020.
  134. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. (April 2020). "Clinical Characteristics of Coronavirus Disease 2019 in China". The New England Journal of Medicine. Massachusetts Medical Society. 382 (18): 1708–1720. doi: 10.1056/nejmoa2002032 . PMC   7092819 . PMID   32109013.
  135. Henry BM (April 2020). "COVID-19, ECMO, and lymphopenia: a word of caution". The Lancet. Respiratory Medicine. Elsevier BV. 8 (4): e24. doi:10.1016/s2213-2600(20)30119-3. PMC   7118650 . PMID   32178774.
  136. Wang L, Wang Y, Ye D, Liu Q (March 2020). "Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence". International Journal of Antimicrobial Agents. 55 (6): 105948. doi:10.1016/j.ijantimicag.2020.105948. PMC   7156162 . PMID   32201353. Archived from the original on 27 March 2020. Retrieved 27 March 2020.
  137. Wang Y, Wang Y, Chen Y, Qin Q (March 2020). "Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures". Journal of Medical Virology. n/a (n/a): 568–576. doi: 10.1002/jmv.25748 . PMC   7228347 . PMID   32134116.
  138. Martel J, Ko YF, Young JD, Ojcius DM (May 2020). "Could nasal breathing help to mitigate the severity of COVID-19". Microbes and Infection. 22 (4–5): 168–171. doi:10.1016/j.micinf.2020.05.002. PMC   7200356 . PMID   32387333.
  139. "Coronavirus recovery : breathing exercises". www.hopkinsmedicine.org. Johns Hopkins Medicine. Retrieved 30 July 2020.
  140. "COVID-19 Treatment Guidelines". www.nih.gov. National Institutes of Health. Retrieved 21 April 2020.
  141. Cheng ZJ, Shan J (April 2020). "2019 Novel coronavirus: where we are and what we know". Infection. 48 (2): 155–163. doi: 10.1007/s15010-020-01401-y . PMC   7095345 . PMID   32072569.
  142. "Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected". World Health Organization (WHO). Archived from the original on 31 January 2020. Retrieved 13 February 2020.
  143. Farkas J (March 2020). COVID-19—The Internet Book of Critical Care (digital) (Reference manual). USA: EMCrit. Archived from the original on 11 March 2020. Retrieved 13 March 2020.
  144. "COVID19—Resources for Health Care Professionals". Penn Libraries. 11 March 2020. Archived from the original on 14 March 2020. Retrieved 13 March 2020.
  145. Roser M, Ritchie H, Ortiz-Ospina E (4 March 2020). "Coronavirus Disease (COVID-19)". Our World in Data. Archived from the original on 19 March 2020. Retrieved 12 March 2020.
  146. 1 2 Yanping Z, et al. (The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team) (17 February 2020). "The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) – China, 2020". China CDC Weekly. Chinese Center for Disease Control and Prevention. 2 (8): 113–122. doi: 10.46234/ccdcw2020.032 . Archived from the original on 19 February 2020. Retrieved 18 March 2020.
  147. 코로나바이러스감염증-19 국내 발생 현황(7월 17일, 정례브리핑) (Report) (in Korean). Korea Centers for Disease Control and Prevention. 17 July 2020. Retrieved 17 July 2020.
  148. Actualización nº 109. Enfermedad por el coronavirus (COVID-19) (PDF) (Report) (in Spanish). Ministerio de Sanidad, Consumo y Bienestar Social. 18 May 2020. Retrieved 20 May 2020.
  149. "Epidemia COVID-19 – Bollettino sorveglianza integrata COVID-19" (PDF) (in Italian). Istituto Superiore di Sanità. 5 June 2020. Retrieved 10 June 2020.
  150. Roser M, Ritchie H, Ortiz-Ospina E (6 April 2020). "Coronavirus Disease (COVID-19)". Our World in Data. Retrieved 6 April 2020.
  151. 1 2 Palmieri L, Andrianou X, Barbariol P, Bella A, Bellino S, Benelli E, et al. (22 July 2020). Characteristics of SARS-CoV-2 patients dying in Italy Report based on available data on July 22nd, 2020 (PDF) (Report). Istituto Superiore di Sanità . Retrieved 4 October 2020.
  152. Baranovskii, D. S.; Klabukov, I. D.; Krasilnikova, O. A.; Nikogosov, D. A.; Polekhina, N. V.; Baranovskaia, D. R.; Laberko, L. A. (19 November 2020). "Prolonged prothrombin time as an early prognostic indicator of severe acute respiratory distress syndrome in patients with COVID-19 related pneumonia". Current Medical Research and Opinion: 1. doi:10.1080/03007995.2020.1853510. ISSN   1473-4877. PMID   33210948 Check |pmid= value (help).
  153. Christensen, Bianca; Favaloro, Emmanuel J.; Lippi, Giuseppe; Van Cott, Elizabeth M. (October 2020). "Hematology Laboratory Abnormalities in Patients with Coronavirus Disease 2019 (COVID-19)". Seminars in Thrombosis and Hemostasis. 46 (7): 845–849. doi:10.1055/s-0040-1715458. ISSN   1098-9064. PMC   7645834 . PMID   32877961.
  154. 1 2 "Living with Covid19". National Institute for Health Research. 15 October 2020. doi:10.3310/themedreview_41169.Cite journal requires |journal= (help)